FDA warned Nutrishus Brands that its RxSugar sweeteners were unapproved new drugs and misbranded foods due to website disease and health claims.
What happened
In May 2021, FDA reviewed therxsugar.com and found the company took orders for RxSugar, RxSugar Organic Liquid Sugar, and RxSugar Organic Pancake Syrup. FDA said website claims tied allulose to obesity, diabetes, inflammation, and heart disease, making the products unapproved new drugs. FDA also said the products were misbranded foods because labels and website claims did not meet food naming, nutrient-content, and Nutrition Facts requirements.
What FDA found
Website claims that the products' allulose may benefit obesity, diabetes, inflammation, or heart disease make them unapproved new drugs.
section 201(g)(1)(B) and 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]The products are misbranded drugs because they lack adequate directions for use for diseases that require a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5RxSugar and RxSugar Organic Liquid Sugar labels do not show the common or usual food name, allulose.
section 403(i)(1) [21 U.S.C. 343(i)(1)]; 21 CFR 101.3(b)(2)The website's 'Healthy' and 'Healthiest' claims are nutrient content claims, but the products do not meet FDA's requirements for 'healthy'.
section 403(r)(1)(A) [21 U.S.C. 343(r)(1)(A)]; 21 CFR 101.65(d)(2)The '90% less Calories than Traditional Sugar' claim lacks the required nearby quantitative comparison to the reference food.
section 403(r)(1)(A) [21 U.S.C. 343(r)(1)(A)]; 21 CFR 101.60(b)(4)The pancake syrup Nutrition Facts label uses the wrong serving size and RACC, and the simplified labels omit a required 'Not a significant source' statement.
section 403(q) [21 U.S.C. 343(q)]; 21 CFR 101.9; 21 CFR 101.9(f)(4)
What FDA wants
FDA asks Nutrishus Brands to respond in writing within 15 working days with the specific corrections it is making, supporting documentation, and plans to prevent recurrence, or to explain why corrections cannot be completed and when they will be.
Who should pay attention
- food brands selling sweeteners or allulose products
- companies making disease or health claims on product websites
- food label compliance and regulatory teams handling nutrient claims
This is a summary. Read the original letter on fda.gov.